Sangamo Biosciences Inc (SGMO)

[jondoeuk]

Over 28 years with no success, allowing others to overtake them, while they created an unsustainable infrastructure. They couldn't even license their AAV capsids or ZFP-TFs, instead having to settle for a nominal "evaluation agreements" with Prevail and Chroma.

Worse still, have around a year of cash on hand unless they decide to address their costs. Does anyone know when the company plans on breaking even? Will it be in '26 or '27 if their haemophilia therapy is approved in '25? Also, they will need to rise, and with the current price it's going to be (extremely) dilutive. If the therapy isn't approved, I don't see how the company isn't toast.